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Abstract: Objective: Five-aminolevulinic acid (5-ALA)-induced porphyrins in malignant 
gliomas are potent photosensitizers. Promising results of ALA-PDT (photodynamic therapy) 
in recurrent glioblastomas have been published. Recently, 5-ALA-induced fluorescence 
was studied in meningioma surgery. Here, we present an experimental study of ALA-PDT 
in an in vitro model of primary meningioma cell lines. Methods: We processed native 
tumor material obtained intra-operatively within 24 h for cell culture. Epithelial membrane 
antigen (EMA) immunohistochemistry was performed after the first passage to confirm 
that cells were meningioma cells. For 5-ALA-PDT treatment, about 5000 cells per well 
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were seeded in 20 wells of a blank 96-well plate. Each block of 4 wells was inoculated 
with 150 µL of 0, 25, 50 and 100 µg/mL 5-ALA solutions; one block was used as negative 
control without 5-ALA and without PDT. Following incubation for 3 h PDT was performed 
using a laser (635 nm, 18.75 J/cm2). The therapeutic response was analyzed by the water 
soluble tetrazolium salt (WST-1) cell viability assay 90 min after PDT. Results: 5-ALA-PDT 
was performed in 14 primary meningioma cell lines. EMA expression was verified in  
10 primary cell cultures. The remaining 4 were EMA negative and PDT was without any effect 
in these cultures. All 10 EMA-positive cell lines showed a significant and dose-dependent 
decrease in viability rate (p < 0.001). Cell survival at 5-ALA concentrations of 12.5, 25, 50 
and 100 μg/mL was 96.5% ± 7.6%, 67.9% ± 29.9%, 24.0% ± 16.7% and 13.8% ± 7.5%, 
respectively. For the negative controls (no 5-ALA/PDT and ALA/no PDT), the viability 
rates were 101.72% ± 3.5% and 100.17% ± 3.6%, respectively. The LD50 for 5-ALA  
was estimated between 25 and 50 µg/mL. Conclusion: This study reveals dose-dependent 
cytotoxic effects of 5-ALA-PDT on primary cell lines of meningiomas. Either 5-ALA or 
PDT alone did not affect cell survival. Further efforts are necessary to study the potential 
therapeutic effects of 5-ALA-PDT in vivo. 
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1. Introduction 
Meningiomas account for 20%–34% of intracranial tumors. With gliomas, they are the most 
common primary intracranial tumors with an annual incidence ranging from two to seven per 100,000 
for women, and from one to five for men [1–3]. Today, computed tomography (CT) and magnetic 
resonance imaging (MRI) diagnosis of meningiomas is often incidental, as patients remain 
asymptomatic for long periods of time due to slow tumor growth [4]. Current standard of care for 
symptomatic tumors is surgical excision of the tumor—as an alternative for smaller and poorly 
accessible lesions—radiosurgery. Despite complete resection, recurrence rates of 10%–20% are 
reported [5–7]. Recurrence rates depend on completeness of resection and the World Health 
Organization (WHO) grade of the meningioma. The recurrence rates of WHO grade III meningiomas 
are reported to be as high as 80% [8,9]. Conventional radiotherapy and radiosurgery were 
recommended as adjuvant therapy for incompletely resected, recurrent, atypical or anaplastic 
meningiomas [10], despite potential serious side effects [3,11–13]. Although 80% of all meningiomas 
may be successfully treated with surgery alone or radiosurgery, five-year control rates for incompletely 
resected and higher grade meningiomas remain poor after either surgery or radiosurgery [8,11,14]. 
Therefore, more effective adjuvant therapies without major side effects are required. 
Five-aminolevulinic acid (5-ALA) has been under close scrutiny for fluorescence-guided resections 
because it elicits the accumulation of fluorescing porphyrins in malignant gliomas [15–20]. These 
porphyrins are also phototoxic and have been explored for photodynamic therapy (PDT) of these  
tumors [18,21–28]. PDT involves the excitation of an administered photosensitizer by light of a 
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specific wavelength to induce energy transfer-producing reactive oxygen species, which then damage 
the DNA, thereby inducing apoptosis or, at higher doses, necrosis [29]. 
An endogenous precursor molecule in the heme synthesis, 5-ALA is metabolized to protoporphyrin 
IX (PPIX). PPIX fluorescence under blue light has been used for intraoperative visualization 
(photodiagnosis) of malignant gliomas [19]. In addition, PPIX is also a potent photosensitizer, making 
it useful for PDT [30]. Ferrochelatase, the terminal enzyme of the heme biosynthetic pathway, 
catalyzes the insertion of iron into PPIX to form heme [31]. Under physiologic conditions, heme 
regulates its own synthesis via a negative feedback loop inhibiting 5-ALA synthase, the first enzyme  
in the heme biosynthetic pathway. Administration of excessive amounts of exogenous 5-ALA causes 
temporary accumulation of PPIX, as ferrochelatase is not immediately capable of converting all the 
PPIX into heme, thus rendering the cells fluorescent and photosensitive. 
Systemic 5-ALA application causes fluorescence of gliomas and also of meningiomas, but not of 
adjacent brain tissue enhancing visual distinction of tumor tissue from brain tissue. This may help to 
improve the extent of resection (photodiagnosis) but may also be used for PDT [19,32]. Experimental 
studies of PDT with 5-ALA confirmed a selective phototoxic effect on glioma cells [21,22] and initial 
effects on inoperable tumors in patients were reported [23]. While PPIX-PDT appears to be effective 
in gliomas, the effectivity of 5-ALA-PDT for meningiomas has yet to be established. A previous study 
comparing ALA-PDT effects between one glioma and one meningioma cell line found a much lower 
effectiveness in the meningioma cell line [24]. In a more recent study of 5-ALA-PDT in two human 
meningioma cell lines, the authors found different 5-ALA induced PDT susceptibilities of the cell 
lines, corresponding to different ferrochelatase activities [33]. 
To assess whether 5-ALA-induced PDT is a useful tool in therapy of malignant and recurrent 
meningioma, a better knowledge of PDT susceptibility of different meningioma cell lines is necessary. 




Of the 14 cell lines that underwent immunohistochemical detection of epithelial membrane antigen 
(EMA), ten (71%) were EMA positive and four (29%) were EMA negative (Figure 1). A highly 
significant (p = 0.002) difference of EMA expression depending on the latency of the first passage 
could be identified, with high EMA expression corresponding to an early passage in average after  
7 days (range 5–10 days). Chi2-test did not reveal any correlation of EMA expression to WHO grade. 




Figure 1. Samples of epithelial membrane antigen (EMA) expression in primary meningioma 
cell lines; magnification ×200-fold. 
2.2. Five-Aminolevulinic Acid (5-ALA) Photodynamic Therapy 
Water soluble tetrazolium salt (WST)-1 cell viability assay showed toxicity to the tested cell lines 
exclusively with the combination of 5-ALA application and laser irradiation. No toxicity (decreased 
cell viability) was detected in wells containing 50 μg/mL 5-ALA not subjected to irradiation, neither 
was toxicity detected in wells without 5-ALA subjected to irradiation (Figure 2). 
No toxicity was seen in EMA negative cell lines. Application of 5-ALA and subsequent PDT was found 
to be toxic in all 10 tested EMA positive cell lines, and toxicity was found to be dose-dependent in all 
cell lines. Cell survival at 5-ALA concentrations of 12.5, 25, 50 and 100 μg/mL were 96.5% ± 7.6%, 
67.9% ± 29.9%, 24.0% ± 16.7% and 13.8% ± 7.5%, respectively. Cell viability decreased significantly 
(p < 0.001) at concentrations 25 μg/mL and above. The viability rates, documented by the WST-1 
assay, are demonstrated in Figure 3. 
Figure 4 demonstrates the course of viability decrease in the ten experiments with EMA-positive cells. 
There was a significant drop from 25 to 50 µg/mL in all trials (p < 0.001). LD50 was estimated between 
25 and 50 µg/mL. The four EMA negative populations showed no significant effect by 5-ALA-PDT. 
 
Figure 2. Negative controls; note: outliers (>1 standard deviation) were marked by stars or circles. 




Figure 3. ALA-PDT showed an ALA dose-dependent decrease of cell viability as measured 
by WST-1 test. Note: the box plots show cell viability rate (%) after 5-ALA-PDT, as measured 
by WST-1 assay for different 5-ALA concentrations (median ± SD). The graph shows the 
means of 10 experiments with EMA positive cells. The LD50 was found to lie between 25 
and 50 µg/mL; note: outliers (>1 standard deviation) were marked by stars or circles. 
 
Figure 4. The courses of cell viability in each experiment. Note: the dashed lines show the 
four EMA negative populations (cases 1–4), the solid lines show the EMA positive 
cultures (cases 5–14). 




In the present study, we demonstrated that 5-ALA-PDT is effective in decreasing viability of primary 
meningioma cell lines in a dose-dependent manner, with an estimated LD50 between 25 and 50 µg/mL. 
Hefti et al. recently reported a very interesting in vitro experiment on two immortalized meningioma 
cell lines (BEN-MEN 1 and HBL-52). Within the same cell lines the results on ALA-PDT were 
reproducible with a high reliability and validity. However, between the two cell lines, they detected  
a variable response to the irradiation therapy [33]. We confirmed these results in 10 primary cell lines  
in vitro. All primary cell lines responded positively to ALA-PDT with a significant decrease in viability 
with increasing concentrations of 5-ALA. The cell lines showed different sensitivities, reflected by the 
high variance and standard deviation at 25 µg/mL. The significance of this high variance compared  
to the other used concentrations remains unclear; however, it may reflect the borderline of the LD50 
between 25 and 50 µg/mL ALA solutions. 
Nevertheless, our results confirm Coluccia’s observations in vivo. The intraoperative use of 5-ALA 
for the visualization of meningiomas showed different fluorescent intensity between and within the 
resected meningiomas [34]. 
The major determinant of recurrence and prognosis in therapy of meningiomas is the extent of 
surgical resection of the tumor. Complete resection may be hindered by infiltration or tight contact to 
dural sinuses, cranial nerves, vessels or brain parenchyma. PDT technically offers a possibility of 
selective destruction of infiltrating tumor tissue, thereby potentially reducing the rate of recurrence.  
The first investigations of PDT of meningiomas were carried out in the 1990s [24,35]. Marks et al. 
found dose-dependent toxicity of PDT in five meningioma cell lines and no toxicity in control cell lines. 
However, the sample size was small and hematoporphyrin derivate (HpD) was used as photosensitizer, 
which is associated with severe adverse effects and is not tumor specific. Rather, it transgresses the  
blood-brain barrier along with edema and is thus unspecific for intracerebral tumor tissue [17,18]. 
A subsequent study of 5-ALA-PDT of immortalized glioma and meningioma cell lines found increased 
fluorescence and PDT sensitivity of glioma cell lines compared to meningioma cell lines [24]. 
Although 5-ALA fluorescence guided resection, and PDT is much more established for gliomas than 
for meningiomas, the potential benefit may be comparable [36–38]. 
Several groups have demonstrated reliable fluorescence of meningiomas after 5-ALA application, 
which reflects substantial PPIX accumulation [29,32,34,39]. However, Hefti et al. revealed inhomogeneity 
of fluorescence within meningiomas [40], a phenomenon also seen in gliomas [15]. This inhomogeneity 
may reflect differences in 5-ALA uptake and metabolism. Genetic inhomogeneity, not uncommon  
for tumors [41,42], may also be a cause of the wide range of 5-ALA-PDT sensitivity found in our 
experiments. Nevertheless, the mechanisms underlying 5-ALA uptake and regulatory mechanisms  
of PPIX synthesis have yet to be fully understood. Increased accumulation of PPIX in malignant and 
pre-malignant tissue compared to healthy tissue may be attributed to either increased 5-ALA uptake, 
increased rate of conversion of 5-ALA to PPIX or decreased rate of conversion of PPIX to heme [16,43]. 
Most efforts focused on regulation of ferrochelatase activity and expression, as studies showed an 
inverse correlation between ferrochelatase expression or activity and PPIX accumulation [9,40,44].  
In order to increase photosensitivity of tumors, future efforts should therefore investigate PDT in 
combination with ferrochelatase inhibitors. 
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4. Experimental Section 
4.1. Meningiomas 
Tumor material used in this study was obtained from 14 patients undergoing surgery for resection of 
a meningioma. There were five (35.8%) males and nine (64.2%) females. Age at resection ranged from 
30 to 82 years with an average of 55.3 years. Twelve were classified as benign (WHO grade I), one  
as atypical (WHO grade II) and one as anaplastic (WHO grade III) according to the WHO 2007 
classification criteria [45]. Informed consent was obtained pre-operatively from each patient. 
4.2. Cell Culture 
Culture of meningioma cells after resection of the tumor was performed by a method adapted from 
Hardy et al. [46]. In preliminary experiments (n = 20), we had modified Hardy’s method continuously 
in order to establish the following procedure in our laboratory: After surgical resection, meningiomas 
were washed in Hank’s balanced salt solution (HBSS) (GIBCO®, Invitrogen, Paisley, UK) and separated 
from macroscopically visible blood vessels and dura mater, before being minced and centrifuged  
(500 rpm/400 G). Tissue was then washed again and incubated at 37 °C with 0.05% Trypsin 
(GIBCO®, Invitrogen, Paisley, UK) for 30 min. Medium (DMEM including Glucose and NEAA 
(GIBCO®, Invitrogen, Paisley, UK) with 10% FCS (PAA Laboratories GmbH, Pausching, Austria), 
1% glutamax, 1% penicillin, 1% streptomycin and 1% amphotericin B (GIBCO®, Invitrogen, Paisley, 
UK)) were added and the tissue centrifuged again before performing another two washing and 
centrifugation steps. The obtained cell pellet was re-suspended in medium in a 0.01% collagen type 
single-coated T25 cell culture flask and cultured as a monolayer. Cells were passaged when a 
confluence of 70% was reached. 
4.3. Immunohistochemistry 
As culture of primary cells often bears the risk of overgrowth of fibroblasts, we immunohistochemically 
stained for EMA, which is a specific marker expressed in meningothelial cells. For immunohistochemical 
detection of EMA, a portion of cells were transferred into a Petri dish containing a cover slip and 
cultured for several days until the cells had overgrown the cover slip. The cover was then fixed in 
acetone at −20 °C for 10 min before being left to air drying for 15 min. The dry cover slip was then glued 
onto a glass slide and was then ready for polymer-conjugated detection of EMA expression by the 
EnVision™ Detection System (Dako, Glostrup, Denmark). This method involves detection of monoclonal 
mouse anti-EMA antibodies by binding of peroxidase–polysaccharidpolymer-conjugated anti-mouse 
secondary antibodies. Firstly, slides were washed in tris buffered saline with tween 20 (TBST,  
DCS Innovative Diagnostik Systeme, Hamburg, Germany), and then incubated in Dako REAL™  
Peroxidase-Blocking Solution (Dako, Glostrup, Denmark) for 10 min. Under subsequent washing, 
slides were incubated in primary antibody (anti-EMA 1:200 in Dako REAL™ Antibody Diluent 
(Dako, Glostrup, Denmark)) and then in secondary antibody (EnVision™-Polymer Solution (Dako, 
Glostrup, Denmark)), each in a humidity chamber for 30 min. The slides were then washed again and 
incubated in substrate chromogen solution (Dako REAL™ DAB + Chromogen 1:50 in Dako REAL™ 
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Substrate Buffer (Dako, Glostrup, Denmark)) for 4–6 min. After washing in demineralized water, they 
were contrasted with hemalaun, dehydrated in ethanol and finally mounted with Eukitt® (Sigma-Aldrich, 
Crailsheim, Germany). 
4.4. Photodynamic Therapy (PDT) 
PDT and control wells were filled with 100 μL of cell solution containing 50 cells per 1 μL medium 
(counted using trypan blue with PBS 1:2 in a Neubauer counting chamber) corresponding to 5000 cells 
per well, whereas blank wells were filled with 100 μL of colorless medium. After incubation for 48 h  
5-ALA powder (Merck, Darmstadt, Germany) was diluted with aqua dest, in a sterile setup avoiding 
direct light, to the required concentration, before 50 μL were added to PDT and control wells. Fifty μL 
of colorless medium were added to blank wells before incubating the microplate in a CO2 incubator for 
4 h (Figure 5). 
 
Figure 5. 96 well microplate setup. 
The irradiation setup used for PDT has been used in the past for PDT of glioma cell lines in our 
laboratory and was developed in cooperation with Welabo GmbH (Düsseldorf, Germany). It includes  
a diode laser (Ceralas 635 Lasersystem, BioLitec GmbH, Jena, Germany), which emits light at  
a wavelength of 635 nm through a fiberglass probe with a diffusor lens, producing a cone of light.  
This allows homogeneous irradiation of the wells of the 96-well microplate. Irradiation of the wells by 
backscatter rays from other wells was avoided by leaving at least two rows of distance between the 
experimental wells. The light source was arranged 9.3 cm from the microplate in order to achieve  
an intensity of 30 mW/cm2, which was executed for 625 s resulting in a radiation dose of 18.75 J/cm2. 
After irradiation, the microplate was returned to the incubator for 90 min before performing the cell 
viability assay (Figure 6). 
  




Figure 6. Photodynamic therapy irradiation setup. 
4.5. WST-1 (Water Soluble Tetrazolium Salt) Cell Viability Assay 
Standard WST-1 assay (protocol and reagents Roche Diagnostics GmbH, Mannheim, Germany), 
which is based on living cells’ capacity to convert red tetrazolium salt into dark red formazan, which 
can be photometrically quantified, was used to determine cell viability after PDT. 
4.6. Data Analysis 
SPSS Statistics 21 (IBM Corporation, Somers, CT, USA), was used to perform Chi2-test, student’s  
t-test, Kruskal–Wallis-Test and one-way ANOVA, in which p < 0.05 and p < 0.01 were considered 
significant and highly significant, respectively. Data was expressed as average ± standard deviation. 
Graphs were created using SPSS. 
5. Conclusions 
Photodynamic therapy using the photosensitizer 5-ALA is effective in a dose-dependent manner  
in primary human meningioma cell lines. Further investigations are necessary to understand the 
transduction pathway of 5-ALA in tumor cells and to understand variation between individual 
meningiomas. This may open the possibility of clinical trials to test the therapeutic effect of ALA-PDT 
in vivo in meningiomas. 
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